Clearside Biomedical (NASDAQ:CLSD) has been selected for inclusion in the NASDAQ Biotechnology Index (NBI). The annual re-ranking of the NBI will become effective at the market open on Dec. 19.
The NBI is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical, according to the industry classification benchmark.
The NBI forms the basis for a number of Exchange Traded Funds (ETFs), including the iShares NASDAQ Biotechnology ETF.
“We are very pleased to be added to the NBI, and look forward to the broader exposure and potential interest in the company among new investors that inclusion provides," Daniel White, president and CEO of Clearside, said in a statement.